Etanercept decreases synovial expression of tumour necrosis factor-α and lymphotoxin-α in rheumatoid arthritis

Apoptosis as a Mechanism of Action of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis

(2012) D. MAKRYGIANNAKIS et al.   JOURNAL OF RHEUMATOLOGY

Lymphotoxin α revisited: general features and implications in rheumatoid arthritis

(2011) Flavia Calmon-Hamaty et al.   ARTHRITIS RESEARCH & THERAPY

Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study

(2009) Clifton O. Bingham et al.   CURRENT MEDICAL RESEARCH AND OPINION

Histological analysis of synovium by treatment of etanercept for rheumatoid arthritis

(2009) Yutaka SUZUKI et al.   International Journal of Rheumatic Diseases

The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab)

(2008) M. H. Buch et al.   RHEUMATOLOGY

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor   expression in the synovium

(2007) C A Wijbrandts et al.   ANNALS OF THE RHEUMATIC DISEASES

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

(2007) Daniel Tracey et al.   PHARMACOLOGY & THERAPEUTICS